HI
HAE icon

Horizon Investments’s Haemonetics HAE Stock Holding History

Horizon Investments’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Sell
13,450
-9,404
-41% -$604K 0.01% 729
2026
Q1 		$1.29M Sell
22,854
-7,069
-24% -$460K 0.01% 594
2025
Q4 		$2.4M Buy
+29,923
New +$2.01M 0.03% 423

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Horizon Investments's HAE Position: Q2 2026 in Review

Horizon Investments reduced its Haemonetics (HAE) stake by 41% in Q2 2026, selling an estimated $604K and leaving 13,450 shares worth $1.01M. The position accounts for 0.01% of the portfolio, ranked #729.

Horizon Investments first reported a position in HAE in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.4M in Q4 2025. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Horizon Investments held 13,450 shares of Haemonetics worth $1.01M as of Q2 2026.
  • Horizon Investments sold 9,404 Haemonetics shares in Q2 2026, an estimated $604K.
  • Haemonetics made up 0.01% of Horizon Investments's portfolio in Q2 2026, its #729 holding.
  • Horizon Investments first reported a position in Haemonetics in Q4 2025 and has held it in 3 quarters since.
  • Horizon Investments's Haemonetics position peaked at $2.4M in Q4 2025.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Horizon Investments's 13F filing for Q2 2026, filed 13 Aug 2026.